Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Clinical Practice Guidelines – Prevention and Management of Dermatological Toxicities Related to Anticancer Agents

Prevention and Management of Dermatological Toxicities Related to Anticancer Agents: ESMO Clinical Practice Guidelines

Published in 2020 – Ann Oncol (2020)
Authors: M.E. Lacouture, V. Sibaud, P.A. Gerber, C. van den Hurk, P. Fernández-Peñas, D. Santini, F. Jahn, K. Jordan on behalf of the ESMO Guidelines Committee

These ESMO Clinical Practice Guidelines provide recommendations on the prevention/management of dermatological toxicities. Authorship includes a multidisciplinary group of experts from different institutions and countries in Europe and abroad. Recommendations for prevention/therapy of acneiform rash, hand-foot syndrome, alopecia, pruritus, paronychia and onycholysis are provided including levels of evidence and grades of recommendation where applicable.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.